摘要
近年来,青光眼的研究焦点已转向神经保护。各种以不同的神经保护药物为基础的实验研究结果表明,神经保护治疗能减少视网膜神经节细胞的损害。针对引起视网膜神经节细胞死亡的不同机制及靶点已开发出多种不同来源的视网膜神经节细胞神经保护药物,这些药物通过多种分子机制及信号通路发挥作用,部分药物已进入临床研究阶段,并有望进入临床使用。
In recent years,the focus of glaucoma research has shifted toward neuroprotection,various neuroprotective drug-based approaches have been shown capable of reducing the death of retinal ganglion cells.In this review,several potential neuroprotective strategies were reviewed.Many of the approaches employ and manipulate the cell′s endogenous mechanism to promote the survival of RCGs.A list of neuroprotective agents are currently undergoing clinical and pre-clinical study.
出处
《医学综述》
2009年第24期3745-3748,共4页
Medical Recapitulate